EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
Affimed tries to convince with seven patients
Luminice-203 yields its first topline data, but where are all the patients?
Revolution sees a new pan-KRAS challenger
Pfizer moves to take PF-07934040 into its first clinical trial.
